2Karel D B, Jef V G. Pharmacology of itraconazole[J]. Drugs, 2001,61(Suppl 1):27. 被引量：1
3Ponec R J, Hackman R C, McDonald G B. Endoscopic and histologic diagnosis of intestinal graft-versus-host disease after marrow transplantation[J]. Gastrointest Endose, 1999,49(5):612. 被引量：1
4De Doncker P, Decroix J, Pierard G E, et al. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole[J]. Arch Dermatol, 1996, 132(1):34. 被引量：1
5Cross L J, Bagg J, Aitchison T C. Efficacy of the cyclodextrin liquid preparation of itraconazole in treatment of denture stomatitis: comparison with itraconazole capsules[J]. Antimicrob Agents Chemother, 2000,44(2):425. 被引量：1
6Barone J A, Moskovitz B L, Guarnieri J, et al. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healthy volunteers[J]. Antimicrob Agents Chemother, 1998,42(7):1862. 被引量：1
7Stevens D A. Itraconazole in cyclodextrin solution[J]. Pharmacotherapy, 1999,19(5):603. 被引量：1
8Prentice H G, Caillot D, Dupont B, et al. Oral and intravenous itraconazole for systemic fungal infection in neutropenic haematological patients: meeting report[J]. Acta Haematol, 1999,101(1):56. 被引量：1
9Cartledge J D, Midgely J, Gazzard B G. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsuples formulation in acquired immunodeficiency syndrome patients with candidosis[J]. J Clin Pathol, 1997,50(6):477. 被引量：1
10Hardin T C, Graybill J R, Fetchick R, et al. Pharmacokinetics of itraconazole following oral administration to normal volunteers[J]. Antimicrob Agents Chemother, 1988,32(9):1310. 被引量：1
